It said the disease makes breathing progressively more difficult for the patients, with symptoms including breathlessness, coughing, and frequent chest infections.
As part of the study, the scientists screened a library of cancer drugs, and identified a number of compounds which accelerate the death of the immune cells called neutrophils, and promote healing in the lungs.
The findings revealed that specific cancer drugs can inhibit a cell signalling process controlling the death-rate of the harmful neutrophils.
Editing the genes coding for the cell signalling, further decreased inflammation, the scientists reported.
"COPD is usually treated with steroids and airway muscle relaxants which ease symptoms, but there is currently no effective treatment clinically available to counteract the damage it does to the lungs," Lynne Prince study co-author from the University of Sheffield.
"Our research now shows that inhibitors of these cell signalling processes, or ErbB kinases, could have therapeutic potential in neutrophilic inflammatory disease," Prince added.
The scientists believe these drugs may clear the damaging cells from the lungs of people living with COPD, preventing any further damage, and therefore the progression of the disease.
They believe repurposing existing drugs, may be an efficient approach for this.
"We are in desperate need of a new treatment for COPD, millions of people all over the world live with the disease and it has a massive impact on their quality of life, especially as the disease progresses," said study co-author Stephen Renshaw.
Since inflammation caused by the neutrophils is also central to the progression of other chronic inflammatory diseases such as rheumatoid arthritis, the researchers believe the findings may offer insights to more such conditions.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.